Coherus Oncology (CHRS) Earnings Date & Reports

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CHRS is expected to report earnings to rise 5.32% to -26 cents per share on July 30

Coherus Oncology CHRS Stock Earnings Reports

Q2'26

Est.

$-0.26

Q1'26

Est.

$-0.25

Q4'25

Est.

$-0.34

Q3'25

Missed

by $0.01

Q2'25

Missed

by $0.08

The last earnings report on May 11 showed earnings per share of -25 cents, meeting the estimate of -25 cents. With 506.40K shares outstanding, the current market capitalization sits at 215.95M.

View a ticker or compare two or three

Compare

CHRS

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for CHRS